Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 187   

Articles published

PFE 29.39 +0.01 (0.03%)
price chart
3 Reasons Pfizer Inc.'s Stock Could Fall
Pfizer (NYSE: PFE ) may be the largest pharmaceutical company in the world, but size isn't everything when it comes to developing and selling drugs.
Related articles »  
Will Pfizer Inc. Make A Bid For GlaxoSmithKline plc?
Specifically, City analysts believe that Pfizer would have to offer a premium of 40%, or just under 2,000p per share. A cost to Pfizer of around $170bn, some analysts believe that this figure is too large even for the world's largest pharmaceutical ...
Related articles »  
Pfizer to test Xalkori lung cancer drug with Merck immunotherapy
(Reuters) - Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.
Merck Collaborates With Pfizer Again For Its PD-1 Immunotherapy  Bidness ETC
Related articles »  
3 Reasons Pfizer Inc.'s Stock Could Rise
Pfizer (NYSE: PFE ) , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to ...
Related articles »  
AstraZeneca rises as investors bet on revival of Pfizer deal
According to reports July 29, 2014, Pfizer Inc.. the second-largest U.S. pharmaceutical maker, posted a 79 percent drop in second quarter profits, but beat analyst expectations.
UK Stocks Rise as AstraZeneca Gains on Pfizer Report  Businessweek
Investors Bet AstraZeneca Megamerger Could Live Again  Bloomberg
Related articles »  
5 Things Pfizer Inc.'s Management Wants You to Know
For the quarter, Pfizer reported that revenue slipped 2%, or $200 million, to $12.77 billion. Profits were also a mixed tale with Pfizer's adjusted income dipping 6% and its adjusted EPS rising 4%. The company also lowered its full-year revenue ...
Pfizer Inc. (PFE): Trouble Ahead For The Stock  ETF Daily News
Intel Corporation (NASDAQ:INTC), Pfizer Inc. (NYSE:PFE), Microsoft ...  US Trade Media
Related articles »  
One Put, One Call Option To Know About for Pfizer
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Pfizer Inc (NYSE: PFE). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Related articles »  
Traders Bank On Pfizer Inc. (PFE) Hurdling Resistance
Pfizer Inc. (NYSE:PFE) calls outstripped puts by a greater than 4-to-1 margin yesterday. Short-term contracts were in vogue, as well, per the stock's 30-day at-the-money implied volatility, which popped 3.7% to 13.3%.
Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog
Pfizer Inc. ( PFE ) announced that its vaccine candidate (PF-06425090) for clostridium difficile infection has been granted fast track designation by the FDA.
Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C ...  Bidness ETC
Pfizer's Investigational Vaccine Candidate for Clostridium difficile ...  MarketWatch
Related articles »  
Pfizer Inc. (NYSE:PFE) Unlikely to Be Successful with Second Bid for ...
Tomahawk, WI 08/26/2014 (Basicsmedia) - AstraZeneca plc (ADR) (NYSE:AZN) shares continue to surge in the market after news emerged that Pfizer Inc. (NYSE:PFE) may table another takeover bid with the three-month ban period that prevented the same ...
Pfizer Inc. (NYSE:PFE) Sets Pace With Palbo Even As The Hunt For Tax ...  FinancialsTrend
Pfizer's Neutral Rating Reaffirmed at Zacks (PFE)  sleekmoney
Related articles »